US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CITIUS ONCOLOGY INC

1.30

-0.3400-20.73%

Post-market: 1.20-0.1000-7.69%18:04 EST

Volume:816.25K

Turnover:1.15M

Market Cap:108.57M

PE:-3.48

High:1.63

Open:1.63

Low:1.27

Close:1.64

52wk High:6.19

52wk Low:0.5506

Shares:83.51M

Float Shares:12.32M

Volume Ratio:0.78

T/O Rate:6.62%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3738

EPS(LYR):-0.3108

ROE:-107.54%

ROA:-22.47%

PB:3.35

PE(LYR):-4.18

Loading ...

Overview Company News Filings

Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma

Citius Oncology Shares Rise After Cancer Treatment Launches

Citius Oncology Announces U.S. Commercial Launch of Lymphir™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (Ctcl)

THOMSON REUTERS

Citius Oncology Showcases LYMPHIR at American Society of Hematology Annual Meeting

Citius Oncology to advance launch of Lymphir with Verix AI integration

Citius Oncology Signs US Distribution Deal With McKesson for Lymphir

MT Newswires Live

BRIEF-Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial Launch

Citius Oncology announces distribution agreement with McKesson

Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4

MT Newswires Live

BRIEF-Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR

Citius Oncology Inc: Co Plans to Commercially Launch Lymphir in United States in Q4 2025

THOMSON REUTERS

Citius Oncology Signs Exclusive Commercialization Agreement With Eversana to Support Planned Q4 2025 Launch of Lymphir™

THOMSON REUTERS

Citius Sets Up Access to Lymphir in Southern Europe

MT Newswires Live

BRIEF-Citius Oncology Enters Exclusive Distribution Agreement With Integris Pharma S.A.

Citius Oncology Inc - Enters Exclusive Distribution Agreement With Integris Pharma S.a.

THOMSON REUTERS

Citius Oncology Raised to Buy From Hold by Maxim Group

Citius Oncology upgraded to Buy from Hold at Maxim

Citius Oncology Inc : Maxim Group Raises to Buy From Hold

THOMSON REUTERS

BRIEF-Citius Oncology Announces Closing Of $9 Million Registered Direct Offering And Concurrent Private Placement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTOR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":1.3,"timestamp":1764709200000,"preClose":1.64,"halted":0,"volume":816248,"hourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.3,"latestTime":"18:04 EST","volume":9529,"amount":11790.593802000001,"timestamp":1764716654958},"delay":0,"floatShares":12321000,"shares":83513442,"eps":-0.373844,"marketStatus":"Post-Mkt","change":-0.34,"latestTime":"12-02 18:05:04 EST","open":1.63,"high":1.63,"low":1.2711,"amount":1151789.5137192,"amplitude":0.218841,"askPrice":1.3,"askSize":20,"bidPrice":1.17,"bidSize":45,"shortable":0,"etf":0,"ttmEps":-0.373844,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.64,"preHourTrading":{"tag":"盘前","latestPrice":1.61,"preClose":1.64,"latestTime":"09:27 EST","volume":41080,"amount":63194.000739999996,"timestamp":1764685640039},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.3,"latestTime":"18:04 EST","volume":9529,"amount":11790.593802000001,"timestamp":1764716654958},"volumeRatio":0.782366},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":12321000,"roa":"-22.47%","roe":"-107.54%","lyrEps":-0.310765,"volumeRatio":0.782366,"shares":83513442,"dividePrice":0,"high":1.63,"amplitude":0.218841,"preClose":1.64,"low":1.2711,"week52Low":0.5506,"pbRate":"3.35","week52High":6.19,"institutionHeld":0,"latestPrice":1.3,"committee":0.384615,"eps":-0.373844,"divideRate":0,"volume":816248,"delay":0,"ttmEps":-0.373844,"open":1.63,"prevYearClose":1.15,"prevWeekClose":1.37,"prevMonthClose":1.37,"prevQuarterClose":2.03,"fiveDayClose":1.12,"twentyDayClose":1.67,"sixtyDayClose":1.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"CTOR","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1758776400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2025-12-01","current":-3.477386,"percent":0.492212,"low":-14.569058,"twenty":-5.90113,"median":-4.300827,"eighty":-3.106212,"high":-1.770477,"avg":-4.643321,"sd":2.013267,"marketCap":114413415},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829},{"date":"2025-06-13","current":-4.04849,"twenty":-4.660231,"median":-3.776135,"eighty":-2.502848,"marketCap":105182030},{"date":"2025-06-20","current":-4.268817,"twenty":-4.617062,"median":-3.83483,"eighty":-2.506208,"marketCap":110906223},{"date":"2025-06-27","current":-9.639263,"twenty":-4.842843,"median":-3.873249,"eighty":-2.506208,"marketCap":250433407},{"date":"2025-07-03","current":-14.569058,"twenty":-5.098498,"median":-3.876214,"eighty":-2.511716,"marketCap":378512206},{"date":"2025-07-11","current":-8.950744,"twenty":-5.244587,"median":-3.890787,"eighty":-2.545647,"marketCap":232545306},{"date":"2025-07-18","current":-4.40652,"twenty":-5.303022,"median":-3.909331,"eighty":-2.598329,"marketCap":114483843},{"date":"2025-07-25","current":-5.370447,"twenty":-5.303022,"median":-3.944397,"eighty":-2.622079,"marketCap":139527183},{"date":"2025-08-01","current":-7.246465,"twenty":-5.617113,"median":-3.968341,"eighty":-2.631999,"marketCap":188267172},{"date":"2025-08-08","current":-6.066045,"twenty":-5.92757,"median":-3.993409,"eighty":-2.65122,"marketCap":157599217},{"date":"2025-08-15","current":-5.071831,"twenty":-5.92757,"median":-4.017441,"eighty":-2.668242,"marketCap":134797404},{"date":"2025-08-22","current":-4.806444,"twenty":-5.916595,"median":-4.026118,"eighty":-2.679481,"marketCap":127744051},{"date":"2025-08-29","current":-6.251327,"twenty":-5.92757,"median":-4.051227,"eighty":-2.692266,"marketCap":166145638},{"date":"2025-09-05","current":-5.514142,"twenty":-5.933303,"median":-4.056957,"eighty":-2.700326,"marketCap":146552992},{"date":"2025-09-12","current":-5.938837,"twenty":-5.933303,"median":-4.063335,"eighty":-2.734303,"marketCap":157840405},{"date":"2025-09-19","current":-5.498923,"twenty":-5.933303,"median":-4.134553,"eighty":-2.759104,"marketCap":146148523},{"date":"2025-09-26","current":-5.71888,"twenty":-5.924891,"median":-4.16145,"eighty":-2.75929,"marketCap":151994464},{"date":"2025-10-03","current":-5.907415,"twenty":-5.938047,"median":-4.221426,"eighty":-2.76177,"marketCap":157005270},{"date":"2025-10-10","current":-5.750303,"twenty":-5.938047,"median":-4.262949,"eighty":-2.769272,"marketCap":152829598},{"date":"2025-10-17","current":-5.624613,"twenty":-5.934887,"median":-4.265883,"eighty":-2.785269,"marketCap":149489061},{"date":"2025-10-24","current":-5.247544,"twenty":-5.933303,"median":-4.296782,"eighty":-2.845783,"marketCap":139467448},{"date":"2025-10-31","current":-5.436079,"twenty":-5.924891,"median":-4.3032,"eighty":-2.870708,"marketCap":144478254},{"date":"2025-11-07","current":-4.524828,"twenty":-5.916595,"median":-4.309619,"eighty":-2.884898,"marketCap":120259356},{"date":"2025-11-14","current":-4.179182,"twenty":-5.914759,"median":-4.309619,"eighty":-2.896465,"marketCap":111072877},{"date":"2025-11-21","current":-3.550733,"twenty":-5.907415,"median":-4.304871,"eighty":-2.952238,"marketCap":94370189},{"date":"2025-11-28","current":-4.304871,"twenty":-5.907415,"median":-4.296782,"eighty":-3.104751,"marketCap":114413415},{"date":"2025-12-01","current":-4.304871,"twenty":-5.90113,"median":-4.300827,"eighty":-3.106212,"marketCap":114413415}],"updateTime":1764711472249},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588970586","title":"Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588970586","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588970586?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:42","pubTimestamp":1764625336,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals Inc. has provided an update on its advanced development programs in the biopharmaceutical sector. The company highlighted the launch of LYMPHIR  in December 2025 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  after at least one prior systemic therapy. LYMPHIR is the first marketed product by Citius Oncology, Inc. , which became a stand-alone public company in August 2024 and remains a majority-owned subsidiary of Citius Pharmaceuticals. Other programs featured include Mino-Lok, a treatment designed to salvage infected catheters causing central line-associated bloodstream infections , which has completed a Phase 3 trial with positive topline data, and Halo-Lido, a prescription therapy in development for hemorrhoids, which has completed a Phase 2b trial. The presentation notes that Citius Oncology has established a shared management services agreement with Citius Pharmaceuticals to support operational efficien","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL2Ff77C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139","CTXR","BK4007"],"gpt_icon":0},{"id":"2588570777","title":"BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2588570777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588570777?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:31","pubTimestamp":1764613866,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell LymphomaDec 1 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA78MRJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2588772937","title":"Citius Oncology Shares Rise After Cancer Treatment Launches","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772937","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772937?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:43","pubTimestamp":1764610980,"startTime":"0","endTime":"0","summary":"Citius Oncology shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin.The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year.Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday.A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months.Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said.Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Citius Oncology Shares Rise After Cancer Treatment Launches","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2588120774","title":"Citius Oncology Announces U.S. Commercial Launch of Lymphir™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (Ctcl)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588120774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588120774?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:00","pubTimestamp":1764608401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA78MRJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","CTXR","BK4139","BK4007"],"gpt_icon":0},{"id":"2586494473","title":"Citius Oncology Showcases LYMPHIR at American Society of Hematology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586494473","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586494473?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:01","pubTimestamp":1764075700,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc. will exhibit at the 67th American Society of Hematology  Annual Meeting & Exposition, taking place December 6-9, 2025, in Orlando, Florida. The company will showcase its FDA-approved therapy, LYMPHIR, for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma, at Booth #265. Company representatives will be available throughout the event to engage with physicians, researchers, and the oncology community.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL5HJn4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"gpt_icon":0},{"id":"2585714636","title":"Citius Oncology to advance launch of Lymphir with Verix AI integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2585714636","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585714636?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:45","pubTimestamp":1763732733,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced a deeper collaboration with Verix, a company in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-to-advance-launch-of-lymphir-with-verix-ai-integration-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-to-advance-launch-of-lymphir-with-verix-ai-integration-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTXR","CTOR","BK4139"],"gpt_icon":0},{"id":"2576857470","title":"Citius Oncology Signs US Distribution Deal With McKesson for Lymphir","url":"https://stock-news.laohu8.com/highlight/detail?id=2576857470","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576857470?lang=en_us&edition=fundamental","pubTime":"2025-10-20 21:36","pubTimestamp":1760967405,"startTime":"0","endTime":"0","summary":"Citius Oncology  said Monday it has signed an agreement naming McKesson  as an authorized US distributor of Lymphir, an immunotherapy for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma.Financial details were not provided.McKesson joins two other distributors, completing the core US distribution network for Lymphir, Citius said.Lymphir has been approved by the US Food and Drug Administration, with a commercial launch planned for Q4, according to the company.Citius shares were up more than 5% in early trading Monday, and McKesson stock was slightly higher.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494708.USD","LU1023059063.AUD","LU0742534661.SGD","LU0868494617.USD","BK4175","LU0861579265.USD","LU0942090050.USD","LU0251131958.USD","LU1814569148.SGD","LU1934455194.USD","LU1037948897.HKD","LU0965509101.SGD","LU1061106388.HKD","LU0048573561.USD","LU0432979614.USD","LU0965508806.USD","LU2089984988.USD","LU2324357040.USD","LU2468319806.SGD","LU1506573853.SGD","LU1366192091.USD","LU1934455277.USD","LU1057294990.SGD","LU0965509283.SGD","LU1585245621.USD","MCK","LU0314106906.USD","BK4533","BK4139","LU1037948541.HKD","LU0203347892.USD","LU0122379950.USD","LU0203345920.USD","LU2112291526.USD","CTOR","BK4585","LU0965509010.AUD","BK4588","LU0251142724.SGD","LU1430594728.SGD","LU1934455863.HKD","LU1983260115.SGD"],"gpt_icon":0},{"id":"2576854147","title":"BRIEF-Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2576854147","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576854147?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:44","pubTimestamp":1760964285,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial LaunchOct 20 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY SIGNS U.S. DISTRIBUTION AGREEMEN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUA7N5VGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","BK4175","LU0203345920.USD","LU0251131958.USD","LU1430594728.SGD","LU0965508806.USD","LU0203347892.USD","LU1366192091.USD","LU1037948541.HKD","LU1061106388.HKD","LU1934455863.HKD","LU2468319806.SGD","LU1057294990.SGD","CTXR","LU0432979614.USD","LU1983260115.SGD","BK4585","BK4007","LU1585245621.USD","LU0868494708.USD","LU0965509101.SGD","LU0048573561.USD","LU0868494617.USD","LU1506573853.SGD","LU1934455194.USD","LU0965509283.SGD","BK4533","LU2089984988.USD","LU0861579265.USD","LU0314106906.USD","LU1814569148.SGD","LU1934455277.USD","LU0942090050.USD","LU1023059063.AUD","MCK","CTOR","LU0742534661.SGD","LU2324357040.USD","LU0965509010.AUD","LU2112291526.USD","LU1037948897.HKD","BK4139","LU0251142724.SGD","BK4588"],"gpt_icon":0},{"id":"2576915854","title":"Citius Oncology announces distribution agreement with McKesson","url":"https://stock-news.laohu8.com/highlight/detail?id=2576915854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576915854?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:40","pubTimestamp":1760964010,"startTime":"0","endTime":"0","summary":"Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has entered into a distribution services agr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-announces-distribution-agreement-with-mckesson-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-announces-distribution-agreement-with-mckesson-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTXR","BK4007","LU0861579265.USD","LU1585245621.USD","LU0251142724.SGD","LU0742534661.SGD","LU0965508806.USD","BK4139","LU2324357040.USD","LU1934455277.USD","LU1037948541.HKD","BK4588","LU1983260115.SGD","LU1037948897.HKD","LU0942090050.USD","LU0965509101.SGD","LU0203345920.USD","LU1934455863.HKD","BK4533","BK4585","LU1023059063.AUD","LU0251131958.USD","LU2468319806.SGD","LU1814569148.SGD","LU1430594728.SGD","MCK","LU2112291526.USD","LU1366192091.USD","LU0048573561.USD","BK4175","LU1061106388.HKD","LU1506573853.SGD","LU2089984988.USD","LU0203347892.USD","LU0868494617.USD","LU0965509010.AUD","LU0965509283.SGD","CTOR","LU1057294990.SGD","LU0314106906.USD","LU1934455194.USD","LU0432979614.USD","LU0122379950.USD","LU0868494708.USD"],"gpt_icon":0},{"id":"2575773744","title":"Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2575773744","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575773744?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:36","pubTimestamp":1760621807,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals'  oncology-focused unit Citius Oncology  said Thursday that it has signed an exclusive agreement with Eversana to support the planned US launch of the cutaneous T-cell lymphoma therapy Lymphir in Q4.Citius Oncology said Eversana will be its exclusive commercialization partner under the master services agreement, providing pre- and post-launch operations services such as medical information, revenue cycle management, and data and analytics.Shares of Citius Oncology were up 26% in recent trading on Thursday, while those of Citius Pharmaceuticals were up 34%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTXR","BK4007","CTOR","BK4139"],"gpt_icon":0},{"id":"2575749696","title":"BRIEF-Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR","url":"https://stock-news.laohu8.com/highlight/detail?id=2575749696","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575749696?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:49","pubTimestamp":1760618964,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIROct 16 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY SIGNS EXCLUSIV","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA1XFCBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTOR","CTXR","BK4139"],"gpt_icon":0},{"id":"2575674950","title":"Citius Oncology Inc: Co Plans to Commercially Launch Lymphir in United States in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575674950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575674950?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:47","pubTimestamp":1760618828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA1XFCBY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTXR","CTOR","BK4139"],"gpt_icon":0},{"id":"2575074950","title":"Citius Oncology Signs Exclusive Commercialization Agreement With Eversana to Support Planned Q4 2025 Launch of Lymphir™","url":"https://stock-news.laohu8.com/highlight/detail?id=2575074950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575074950?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:47","pubTimestamp":1760618828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA1XFCBY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","CTXR","CTOR"],"gpt_icon":0},{"id":"2573966243","title":"Citius Sets Up Access to Lymphir in Southern Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2573966243","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573966243?lang=en_us&edition=fundamental","pubTime":"2025-10-07 23:04","pubTimestamp":1759849454,"startTime":"0","endTime":"0","summary":"Citius Oncology  said Tuesday it has entered into an exclusive distribution agreement with Greece-based Integris Pharma to make Lymphir available in Southern Europe.The partnership coverage includes Greece, Cyprus, Malta, Bulgaria, and Romania, it said. Lymphir is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma.The deal is part of its Named Patient Programs, also known as early access programs, Citius said, adding that it is in discussions with distribution partners to make the drug available through the program in Europe, South America and the Middle East.Price: 1.90, Change: +0.03, Percent Change: +1.66","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BMG7P926.USD","LU0320765646.SGD","LU1732799900.SGD","LU2384288077.EUR","IE00BMG7P587.USD","LU1267930490.SGD","IE00B29SXK94.USD","LU1718418525.SGD","BK4585","LU0070217475.USD","LU2347655073.USD","LU0795875169.SGD","IE00BMG7P819.SGD","IE00B29SXL02.USD","LU2347655156.SGD","LU1621767810.EUR","LU1621767737.EUR","CTOR","LU1621768206.USD","LU1621768115.EUR","LU0912757837.SGD","LU1732800096.USD","LU0726765562.USD","LU0310799852.SGD","LU1929549753.HKD","LU0211327993.USD","BK4081","LU2133065610.SGD","LU0795875086.SGD","LU0211328371.USD","LU1162221912.USD","BK4588","SO","IE00BMG7P694.USD","LU0098860793.USD","BK4139"],"gpt_icon":0},{"id":"2573192950","title":"BRIEF-Citius Oncology Enters Exclusive Distribution Agreement With Integris Pharma S.A.","url":"https://stock-news.laohu8.com/highlight/detail?id=2573192950","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573192950?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:52","pubTimestamp":1759841555,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Enters Exclusive Distribution Agreement With Integris Pharma S.A.Oct 7 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY INC - ENTERS EXCLUSIVE DISTRIBUTION AGREEMENT WITH I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO026:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2573295098","title":"Citius Oncology Inc - Enters Exclusive Distribution Agreement With Integris Pharma S.a.","url":"https://stock-news.laohu8.com/highlight/detail?id=2573295098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573295098?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:48","pubTimestamp":1759841334,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO026:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2569654797","title":"Citius Oncology Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2569654797","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569654797?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:57","pubTimestamp":1758628620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 23, 2025 07:57 ET (11:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2569920427","title":"Citius Oncology  upgraded to Buy from Hold at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2569920427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569920427?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:30","pubTimestamp":1758627017,"startTime":"0","endTime":"0","summary":"Maxim analyst Michael Okunewitch upgraded Citius Oncology (CTOR) to Buy from Hold with a $6 price target Published first on TheFly – the ultimate s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-upgraded-to-buy-from-hold-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-upgraded-to-buy-from-hold-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2569792629","title":"Citius Oncology Inc : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2569792629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569792629?lang=en_us&edition=fundamental","pubTime":"2025-09-23 19:27","pubTimestamp":1758626874,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nFWN3VA0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2566982490","title":"BRIEF-Citius Oncology Announces Closing Of $9 Million Registered Direct Offering And Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2566982490","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566982490?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:34","pubTimestamp":1757536476,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Announces Closing Of $9 Million Registered Direct Offering And Concurrent Private PlacementSept 10 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY ANNOUNCES CLOSING OF $9.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUABKV5FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CTOR","CTXR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}